Patients, pharmacies, and insurers scramble to adapt as GSK protects profits by discontinuing Flovent while authorizing a generic inhaler.January 5, 2024Check out STAT+Sponsored By Adobe STAT+ | GSK is replacing its popular Flovent inhaler with authorized generics, raising cost concerns for asthma patients Patients, pharmacies, and insurers scramble to adapt as GSK protects profits by discontinuing Flovent brand name while authorizing a generic inhaler. By Annalisa Merelli Biden's FDA is letting Ron DeSantis import cheaper drugs from Canada. Who gets to take credit? The approval of Florida's plan to import Canadian drugs is expected to set in motion legal battles and a political fight for credit. By John Wilkerson STAT+ | Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi Tousi is the fourth senior executive to leave Illumina since June, when CEO Francis deSouza abruptly resigned. By Jonathan Wosen Adobe Opinion: I went on a mind-boggling journey to get my son's ADHD medication covered by insurance — twice U.S. insurers employ a secretive and complicated process for deciding what drugs to cover. Here's what I learned about fighting back. By Craig Idlebrook A young dancer, diagnosed with scoliosis, learns to advocate for herself and build community After receiving a scoliosis diagnosis, a young dancer started her freshman year of high school wearing a back brace for 18 hours a day. By Anika Nayak Opinion: The misguided reason why providers aren't prescribing more buprenorphine for opioid use disorder Despite providers' fears about diversion, non-prescribed buprenorphine could be considered a harm reduction measure. By Joëlla W. Adams More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments